Sterilisation and infection control market: size, growth and outlook 2026–2032

Infection-control spend is small until an outbreak; CSSD outsourcing is the new PPP line. Published estimates normalised to 2025 range from USD 3.8 bn to USD 57.3 bn; the Consulting Wallah central estimate is USD 57.0 bn, growing at about 6% a year to USD 88.6 bn by 2032. Scope differences between publishers explain most of the spread — the comparison table below states each one.

Growth is driven by rising HAIs (7-15% of acute-care patients per WHO) and infection-control regulation; growing surgical and endoscopic procedure volumes requiring instrument reprocessing; hospital capacity build-out in Saudi Arabia and India (Saudi steriliser market growing 8.2%, India 7.7%).

Context that matters for buyers and suppliers: Global infection control market grew from USD 54.32 bn (2024) to USD 57.31 bn (2025); described as moderately consolidated. Equipment is ~55% of sterilization spend; hospitals & clinics ~35.9% of end use; North America ~46%. WHO: ~7 of 100 hospitalised patients in high-income and ~15 of 100 in low/middle-income countries acquire at least one HAI. Off-site sterilisation services held the larger share in 2024; EtO is the leading method.

The chart shows the Consulting Wallah central estimate: published figures normalised to 2025, median taken, and projected at the median published growth rate. The published range for 2025 is USD 3.8 bn–USD 57.3 bn; differences are mostly scope.

Included: the product category as named, across hospital, clinic, laboratory and home settings, including the consumables and service contracts that travel with it where sources report them together. Excluded: adjacent categories reported in their own markets. Global figures are quoted as published; regional figures are flagged by scope.

Shares as reported by the named sources; ranking is more reliable than the exact percentage.

• Global infection control market grew from USD 54.32 bn (2024) to USD 57.31 bn (2025); described as moderately consolidated (MarketsandMarkets)
• Equipment is ~55% of sterilization spend; hospitals & clinics ~35.9% of end use; North America ~46% (Meticulous Research)
• WHO: ~7 of 100 hospitalised patients in high-income and ~15 of 100 in low/middle-income countries acquire at least one HAI (Meticulous Research citing WHO)
• Off-site sterilisation services held the larger share in 2024; EtO is the leading method (MarketsandMarkets)
• STERIS R&D spend USD 98-107 mn annually; acquired BD's surgical and sterilization assets in 2023 (MarketsandMarkets)
• Surgical instrument sterilisation was 18.6% of Servizi Italia's 2024 revenues (USD 314.2 mn total) (MarketsandMarkets)
• India sterilization equipment market (USD 580 mn) is ~3.5x Saudi Arabia's (USD 164 mn) in 2025, both growing ~8% (IMARC Group)

Where the GCC and India sit

• Saudi Arabia sterilization equipment: USD 164.3 mn (2025) -> USD 333.1 mn (2034), 8.17% CAGR (2025) — IMARC Group
• India sterilization equipment: USD 579.8 mn (2025) -> USD 1,153.8 mn (2034), 7.71% CAGR (2025) — IMARC Group
• North America share of sterilization equipment: ~46% (2025) — Meticulous Research
• HAI incidence (WHO): ~7 of 100 acute-care patients in high-income countries and ~15 of 100 in LMICs acquire at least one HAI (2025) — Meticulous Research citing WHO

Consulting Wallah works this market from both sides: hospital groups in the UAE, Saudi Arabia, India and Bangladesh as buyers, and manufacturers in India, China, Singapore, Malaysia and the US as suppliers through the Network. Our observation is that registration status, in-country stock and structured quotations decide access in the GCC, while price and distributor reach decide it in India. CW observation

Opportunities we see: outsourced CSSD / off-site sterilisation services for multi-hospital groups (off-site already the larger delivery mode); e-beam, X-ray, CO2 and nitrogen dioxide sterilisation as EtO alternatives; digital instrument tracking, biological/chemical indicators and steam monitoring products.

Key companies named across the sources; local distributors and implementation partners matter as much as the brand in the GCC and India.

• Hospital leaders: standardise the fleet or the product family across sites, tender on total cost of use with fill-rate and uptime KPIs, and dual-source the top lines — see our five-line scoring.
• Suppliers: GS1 data, in-country stock and service response are the differentiators after price; the Consulting Wallah Network carries GCC and Indian demand in this category.
• Investors: regional manufacturing or service capacity backed by procurement preference.

1. MarketsandMarkets, Infection Control Market Size Worth USD 77.67 Billion by 2030 — marketsandmarketsblog.com
2. Meticulous Research / PRNewswire via finanzen.net, Sterilization Equipment Market to Reach USD 29.2 Billion by 2032 (8.2% CAGR) — finanzen.net
3. MarketsandMarkets via finanzen.net, Sterilization Services Market worth USD 5.49 billion by 2030 with 7.9% CAGR — finanzen.net
4. IMARC Group, Saudi Arabia Sterilization Equipment Market 2026-2034 — imarcgroup.com
5. IMARC Group, India Sterilization Equipment Market 2026-2034 — imarcgroup.com
6. MarketsandMarkets (2025-11) — USD 57.31 bn (2025) to USD 77.67 bn (2030), CAGR 6.3% (2025-2030); scope: Global infection control (sterilisation products & services, cleaning & disinfection, protective barriers, endoscope reprocessing); 2024 = USD 54.32 bn; cleaning & disinfection largest segment; hospitals largest end user; North America largest region — source
7. Meticulous Research (via PRNewswire/finanzen.net) (2025-06) — ~USD 16.8 bn (est.) (2025) to USD 29.2 bn (2032), CAGR 8.2% (2025-2032); scope: Global sterilization equipment & services; equipment ~55% of 2025 market; hospitals & clinics ~35.9%; North America ~46% — source
8. MarketsandMarkets (2025-09) — USD 3.75 bn (2025) to USD 5.49 bn (2030), CAGR 7.9% (2025-2030); scope: Global sterilization services (contract/outsourced); 2024 = USD 3.52 bn; off-site larger than on-site; EtO largest method — source
9. Consulting Wallah Network — anonymised observations from procurement and business-setup work with hospital groups and suppliers in the UAE, India and Bangladesh (2024–26), used for the GCC/India outlook and the “what it means” section.
10. Method. Each published figure is normalised to a 2025 base using its own CAGR; the Consulting Wallah central estimate is the median of the normalised figures (or the stated scope where noted) projected at the median CAGR to 2032. Country figures are quoted as published; where we add a CW estimate it is labelled.